Morgan Stanley calls for a 26% gain in this under-the-radar ‘safe port in the storm’
Morgan Stanley says investors looking for a hideout in this volatile market should consider putting their money in this lesser known biotechnology stock. Analyst Andrew Galler initiated coverage of Halozyme…